Glaxo Increases OTC Medicines With New Cold Sore Cream
GlaxoSmithKline and Medivir announced today an exclusive agreement for the commercialization of a new over the counter cold sore cream. Xerclear is the new product that will contain acyclovir and hydrocortisone for non-prescription use in multiple markets, including 14 major European countries.
This should bolster Glaxo’s over the counter medicine business. According to reports,
Swedish-based Medivir will get up to 3 million euros ($4 million) in upfront and pre-launch milestone payments, as well as up to double-digit percentage royalties on sales.
The new combo was granted marketing approval in in last October and is based on strong clinical data. Xerclear was given “a unique label, which differentiates it from other topical cold sore products currently on the market,” GSK says.
According to the Pharma Times,
The treatment, previously known as Lipsovir, will be distributed as part of GSK’s over-the-counter Zovirax (acyclovir) franchise in multiple markets, including Europe, Russia, Japan, India, Australia and New Zealand but not North and South America, China, South Korea and Israel. The drugs giant will pay up to 3 million euros in upfront and pre-launch milestones and up to double-digit royalties.
Only time will tell if Xerclear will ever make it to market in the US.
Tweet
